Recent developments include financing to advance the influenza program, completion of Phase 2 enrollment for Ratutrelvir, regulatory setbacks, and clinical data announcements.

• Traws Pharma secured up to $60 million in financing to advance its influenza program as of April 15, 2026 [N3].
• The company completed enrollment in a Phase 2 study of Ratutrelvir and expanded the TXM program to influenza indications as of January 27, 2026 [N5].
• Traws Pharma's stock price climbed 20% following news of its hantavirus drug development efforts on May 8, 2026 [N1].
• The FDA halted the TXM IND, causing a significant stock price decline on February 19, 2026 [N4].
• The company announced the IND filing of Tivoxavir Marboxil on January 13, 2026 [N7].
• Ratutrelvir showed activity in PAXLOVID-ineligible COVID-19 patients with final data due in January 2026 [N8].

The company has advanced multiple drug candidates through clinical development, including positive Phase 1 and Phase 2 data for Ratutrelvir and promising preclinical data for Tivoxavir Marboxil. Securing up to $60 million in financing supports ongoing development efforts. Expansion of the TXM program to influenza and activity in PAXLOVID-ineligible COVID-19 patients indicate potential for addressing significant patient populations. The leadership team's experience and recent clinical milestones provide a foundation for continued progress.

Traws Pharma faces regulatory risks exemplified by the FDA halting the TXM IND, which may delay or complicate development. The company reported a net loss and a current ratio below 1, indicating liquidity constraints. Clinical development is inherently uncertain, and financing needs may persist. Market volatility in the company's stock price reflects sensitivity to clinical and regulatory news, underscoring execution risks.

Traws Pharma's moat is primarily based on its clinical-stage drug candidates targeting infectious diseases with unmet medical needs, supported by its regulatory filings and clinical data. The company's leadership team brings extensive pharmaceutical industry experience, which may aid in navigating development and regulatory pathways. However, as a clinical-stage company, it faces typical biotech risks including regulatory approvals, clinical trial outcomes, and financing needs.

• Regulatory Risk: The FDA halted the TXM IND, demonstrating regulatory challenges that could delay or prevent drug approvals.
• Financial Risk: The company reported a net loss of $7.11 million for Q1 2026 and has a current ratio of 0.43 as of March 31, 2026, indicating potential liquidity constraints.
• Clinical Development Risk: Clinical trials for drug candidates such as Ratutrelvir and Tivoxavir Marboxil carry inherent uncertainties in outcomes and timelines.
• Market and Stock Volatility: The company's stock price has shown significant volatility in response to clinical and regulatory developments.

• Traws Pharma, Inc. is a pharmaceutical company engaged in drug development, including treatments for infectious diseases such as COVID-19, influenza, and hantavirus.
• The company has multiple drug candidates in clinical development, including Ratutrelvir and Tivoxavir Marboxil.
• Ratutrelvir has completed enrollment in a Phase 2 study and is being evaluated as a treatment for COVID-19, including activity in patients ineligible for PAXLOVID, with final data due in January 2026.
• Tivoxavir Marboxil has been filed for IND and shows positive preclinical data in non-human primates for bird flu (avian influenza).
• The company expanded its TXM program to include influenza indications.
• Traws Pharma secured up to $60 million in financing to advance its influenza program as of April 2026.
• The company experienced a regulatory setback when the FDA halted the TXM IND, impacting development timelines.
• Traws Pharma's stock price showed volatility in response to clinical and regulatory news, including a 20% climb on hantavirus drug development news and a plunge following the FDA halt of TXM IND.
• The company has a board of directors and executive leadership with extensive pharmaceutical industry experience, including CEO Dr. Iain Dukes and Chairman Jack E. Stover.
• As of March 31, 2026, the company reported cash and equivalents of approximately $20.56 million, current assets of $5.67 million, and current liabilities of $13.21 million, resulting in a current ratio of 0.43 and a cash ratio of 1.56.
• For the quarter ended March 31, 2026, Traws Pharma reported a net loss of $7.11 million and basic and diluted EPS of -$0.53.
• The company reported revenues of $2.79 million for the fiscal year ended December 31, 2024.
• The company has adopted corporate governance policies including a code of conduct and insider trading policy.
• The company has ongoing clinical programs with regulatory filings and briefing documents submitted to the FDA for its drug candidates.
• The company has publicly disclosed risk factors including the need for additional financing, regulatory risks, and clinical trial uncertainties.
• The company completed a private placement financing involving common stock and warrants in April 2026.
• The company has a history of clinical data publications and regulatory submissions for its drug candidates.
• The company is listed on the Nasdaq Stock Market under the ticker TRAW.